NIH Clinical Center

This file is provided for reference purposes only. It was current when it was produced, but it is no longer maintained and may now be out of date. Persons with disabilities having difficulty accessing information may contact us for assistance. For reliable, current information on this and other health topics, we recommend consulting the NIH Clinical Center at http://www.cc.nih.gov/.

Major Programs: Warren Grant Magnuson Clinical Center: Clinical Center Profile 2002


Breakdown of Clinical Trials
(Onsite Intramural Protocols) Fiscal Year 2001

Clinical Trials Proceed Through Four Phases

Phase I: Researchers test a new drug or treatment in a small group of people (20 – 80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

Phase II: The study drug or treatment is given to a larger group of people (100 – 300) to see if it is effective and to further evaluate its safety.

Phase III: The study drug or treatment is given to large groups of people (1,000 – 3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will ensure safe usage.

Phase IV: These studies are done after the drug or treatment has been marketed. The testing continues to collect information about the effect of the drug or treatment in various populations and determine any side effects from long-term use.

Chart: Total Clinical Trials 524; Phase I: 196 (37%) Phase II: 279 (53%) Phase III: 36 (7%) Phase IV: 13 (3%)


See more information:
Protocols by Research Type >
Patient Census >
Service Intensity >
Home States of all Active Clinical Center Patients >

< Return to the Major Programs main page

End of right navigation list link group.





The information on this page is archived and provided for reference purposes only.


National Institutes
of Health
  Department of Health
and Human Services